ipilimumab + nivolumab + stereotactic body radiation therapy

Ipilimumab is a human monoclonal antibody biologic that targets the immune checkpoint receptor CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). In the RADVAX RCC clinical trial led by the University of Texas Southwestern Medical Center, ipilimumab is utilized in a combination regimen with nivolumab (a PD-1 inhibitor) and stereotactic body radiation therapy (SBRT) for patients with metastatic clear-cell renal cell carcinoma. This therapeutic approach aims to leverage the abscopal effect, where localized radiation (SBRT) to metastatic sites potentially enhances the systemic anti-tumor immune response triggered by dual checkpoint blockade. The regimen typically involves an induction phase of ipilimumab and nivolumab administered intravenously alongside SBRT, followed by maintenance therapy with nivolumab monotherapy.

Brand names

YervoyOpdivo

Other names

ipilimumab-University of Texas Southwestern Medical Center-renal cell carcinoma (metastatic)RADVAX regimenSBRT + Nivolumab + Ipilimumab